Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP Pres MedSurg | February 28, 2022 | March 02, 2022 |
| DIVERSIFIED HEALTHCARE TRUSTNASDAQ:DHC · Entity 4565 | Director | June 05, 2023 | June 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 28, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-03-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-02-28 · Exercise / conversion · Acquired 2,444 · Balance 2,444 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 2 · 2022-02-28 · Tax withholding · Disposed 718 · Balance 1,726 Row 3 · 2022-03-01 · Sale · Disposed 1,726 · Balance 0 F2: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-02-28 | Direct | 0 |
Reported balance
After 2022-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-28 · Exercise / conversion · Disposed 2,444 · Balance 0 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.
F3: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
DIVERSIFIED HEALTHCARE TRUST
Report date June 05, 2023 · Filed June 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 40,000 |
Reported balance
After 2023-06-05 transaction · row 1
1 source rowRow 1 · 2023-06-05 · Grant · Acquired 20,000 · Balance 40,000 F1: Transaction reported is grant of shares pursuant to the Issuer's equity compensation plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction reported is grant of shares pursuant to the Issuer's equity compensation plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2018 Filed Jun 4, 2018 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-010105 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,000 | $7.16 | $35,800.00 |
DisclosureSEC source: 0001225208-18-010105 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| May 01, 2018 Filed May 2, 2018 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-008510 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,640 Underlying: Common Stock · 5,000 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase 77,640 shares of common stock vesting in four annual increments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| May 01, 2018 Filed May 2, 2018 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 5,000 | $28.80 | $143,981.50 |
DisclosureSEC source: 0001225208-18-008510 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| May 01, 2018 Filed May 2, 2018 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,000 | $7.16 | $35,800.00 |
DisclosureSEC source: 0001225208-18-008510 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 20:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-007153 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,640 Underlying: Common Stock · 5,000 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase 77,640 shares of common stock vesting in four annual increments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 20:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 5,000 | $27.22 | $136,124.50 |
DisclosureSEC source: 0001225208-18-007153 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 20:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,000 | $7.16 | $35,800.00 |
DisclosureSEC source: 0001225208-18-007153 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 3,800 | $27.00 | $102,600.00 |
DisclosureSEC source: 0001225208-18-005415 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-005274 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,640 Underlying: Common Stock · 5,000 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase 77,640 shares of common stock vesting in four annual increments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 5,000 | $27.19 | $135,957.50 |
DisclosureSEC source: 0001225208-18-005274 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,001 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,000 | $7.16 | $35,800.00 |
DisclosureSEC source: 0001225208-18-005274 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004949 · doc4.xml · derivative · entry 6 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,776 Underlying: Common Stock · 2,443 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004949 · doc4.xml · derivative · entry 5 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,398 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 4,508 | $27.54 | $124,170.61 |
DisclosureSEC source: 0001225208-18-004949 · doc4.xml · nonDerivative · entry 4 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,001 F2 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $27.52 and $27.575. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 3,041 | $27.26 | $82,897.66 |
DisclosureSEC source: 0001225208-18-004949 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,509 Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004949 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004949 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 22:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004205 · doc4.xml · derivative · entry 6 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,058 Underlying: Common Stock · 3,058 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 22:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,360 | $27.20 | $36,992.00 |
DisclosureSEC source: 0001225208-18-004205 · doc4.xml · nonDerivative · entry 4 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,709 Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 22:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004205 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 22:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004205 · doc4.xml · derivative · entry 5 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,906 Underlying: Common Stock · 2,452 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 22:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,090 | $27.20 | $29,648.00 |
DisclosureSEC source: 0001225208-18-004205 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,011 Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 22:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004205 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004012 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,821 Underlying: Common Stock · 2,607 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,159 | $26.48 | $30,690.32 |
DisclosureSEC source: 0001225208-18-004012 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,649 Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004012 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 21:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 16,286 | $27.00 | $439,722.00 |
DisclosureSEC source: 0001225208-18-004012 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $27.00 and $27.005. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 41,713 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-18-003400 · doc4.xml · derivative · entry 2 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,713 Underlying: Common Stock · 41,713 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 13,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003400 · doc4.xml · derivative · entry 1 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,842 Underlying: Common Stock · 13,842 shares Expires 2023-02-15 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 11,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-002899 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,926 Underlying: Common Stock · 11,926 shares Expires 2019-12-31 F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F3 · derivative.exercise_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F3 · derivative.expiration_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F3 · balance_after: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 8,238 | $26.18 | $215,670.84 |
DisclosureSEC source: 0001225208-18-002899 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,487 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 24,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-002899 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,725 F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2017 and was subject to the completion of the concurrent three-year individual service period. On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 01, 2018 Filed Feb 1, 2018 21:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,152 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-18-001990 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,152 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2011, the first anniversary of the date of grant. Read SEC document |
| February 01, 2018 Filed Feb 1, 2018 21:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 5,152 | $27.43 | $141,319.36 |
DisclosureSEC source: 0001225208-18-001990 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 01, 2018 Filed Feb 1, 2018 21:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,152 | $7.41 | $38,176.32 |
DisclosureSEC source: 0001225208-18-001990 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| January 11, 2018 Filed Jan 11, 2018 21:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 8,763 | $27.74 | $243,074.23 |
DisclosureSEC source: 0001225208-18-000939 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,152 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-18-000900 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,152 Underlying: Common Stock · 5,152 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2011, the first anniversary of the grant. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 5,152 | $27.00 | $139,104.00 |
DisclosureSEC source: 0001225208-18-000900 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,964 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,152 | $7.41 | $38,176.32 |
DisclosureSEC source: 0001225208-18-000900 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP,Pres Urology,Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 23:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 13,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000432 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,341 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.exercise_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.expiration_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 23:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 4,578 | $24.79 | $113,488.62 |
DisclosureSEC source: 0001225208-18-000432 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,964 Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 23:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 13,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000432 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,062 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-17-011120 · doc4.xml · derivative · entry 5 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,934 Underlying: Common Stock · 4,062 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001225208-17-011120 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,929 Underlying: Common Stock · 9,500 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 13,562 | $28.00 | $379,736.00 |
DisclosureSEC source: 0001225208-17-011120 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,062 | $7.39 | $30,018.18 |
DisclosureSEC source: 0001225208-17-011120 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 9,500 | $13.08 | $124,260.00 |
DisclosureSEC source: 0001225208-17-011120 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 2,972 | $27.70 | $82,313.40 |
DisclosureSEC source: 0001225208-17-010882 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F2 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-010882 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,889 Underlying: Common Stock · 2,972 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.